Physician

Chalit Wanthakawikran, MD

According to 2025 Medicare claims, Chalit Wanthakawikran, MD (NPI: 1376700161) practices nephrology in the Laredo, TX market, with the plurality of this provider's patient population coming from Webb, TX. This provider's primary affiliated billing organization is LAREDO NEPHROLOGISTS PLLC (NPI: 1295075927; TIN: 462049200) and primary practice location at 78041-5434.

Wanthakawikran's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 353 traditional Medicare patients, billed 1,451 HCPCS/CPT codes, and received $195,041 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,295 prescription claims across 482 beneficiaries totaling $746,858 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 150 claims. Open Payments data shows 7 records totaling $222. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $623,643 and ending at $746,858. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	609	3,599	$326,179
2016	688	4,413	$385,661
2017	720	4,285	$396,089
2018	693	4,523	$489,503
2019	786	4,682	$496,867
2020	706	3,672	$468,365
2021	584	2,470	$386,326
2022	513	2,272	$327,955
2023	423	1,755	$239,566
2024	353	1,451	$195,041

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	339	2,109	$623,643
2016	323	1,841	$934,666
2017	404	2,136	$1,210,635
2018	452	2,363	$1,000,028
2019	452	2,122	$684,074
2020	416	1,875	$655,792
2021	369	1,745	$791,833
2022	402	1,863	$1,054,979
2023	449	2,014	$758,528
2024	482	2,295	$746,858

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	56	$2,498
2016	N/R	79	$2,772
2017	N/R	62	$1,742
2018	N/R	89	$3,628
2019	N/R	159	$5,959
2020	N/R	28	$1,294
2021	N/R	109	$4,085
2022	N/R	115	$2,092
2023	N/R	112	$2,072
2024	N/R	150	$2,364

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	116	375	$267
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	47	49	$130
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	59	139	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	81	276	$60
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	122	312	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	77	2,790	$214,032
Veltassa	Patiromer Calcium Sorbitex	58	2,842	$91,364
Auryxia	Ferric Citrate	65	3,270	$83,667
Farxiga	Dapagliflozin Propanediol	73	4,290	$78,415
Lokelma	Sodium Zirconium Cyclosilicate	67	2,900	$70,698

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	45	$867
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	37	$696
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	36	$412
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	32	$389

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$222	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chalit Wanthakawikran, MD?

Tedicare shows public-source Medicare data for Chalit Wanthakawikran, MD (NPI 1376700161), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chalit Wanthakawikran, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chalit Wanthakawikran, MD?

Chalit Wanthakawikran, MD is linked to LAREDO NEPHROLOGISTS PLLC (billing NPI 1295075927) in the available physician profile data.

Does Chalit Wanthakawikran, MD have Open Payments data?

Chalit Wanthakawikran, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.